Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

NCT00199901 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: NY-ESO-1 ISCOMATRIX®
BIOLOGICAL: ISCOMATRIX® adjuvant

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]